Sessions at the major heart associations' annual meetings featuring “late-breaking” results from clinical trials are highly anticipated occasions offering clinicians glimpses at important findings that could have practice-changing implications. But at the American Heart Association's (AHA’s) annual meeting in Dallas, the perception, at least among some attendees, was that for an unusually large number of “late-breaking” clinical trials that were given the spotlight, researchers found no benefit from the intervention being studied.
Do Lackluster Trial Findings Mean New Avenues Are Needed for Heart Research?. JAMA. 2006;295(6):611-612. doi:10.1001/jama.295.6.611